Erschienen in:
25.02.2021 | Original Article
Age and comorbidity are determining factors in the overall and relative survival of patients with follicular lymphoma
verfasst von:
Pablo Mozas, Andrea Rivero, Alfredo Rivas-Delgado, Ferran Nadeu, Juan Gonzalo Correa, Carlos Castillo, Alex Bataller, Tycho Baumann, Eva Giné, Julio Delgado, Neus Villamor, Elías Campo, Laura Magnano, Armando López-Guillermo
Erschienen in:
Annals of Hematology
|
Ausgabe 5/2021
Einloggen, um Zugang zu erhalten
Abstract
Frailty and concurrent medical conditions are crucial factors in the management of follicular lymphoma (FL). We evaluated the impact of age and comorbidity on survival, causes of death, histological transformation (HT), and second malignancies (SM) in a large single-center series of grade 1–3A FL. We studied 414 patients diagnosed in the rituximab era, categorized into three age groups (≤60, 61–70, >70 years) and two comorbidity groups (Charlson Comorbidity Index, CCI, 0–1 and ≥2). Despite a similar cumulative incidence of relapse, older and comorbid patients had a lower 10-year overall survival (OS, 88, 65, and 41% for patients ≤60 years, 61–70 years, and >70 years, P<0.0001; and 76 vs. 51% for CCI 0–1 and ≥2, P<0.0001). In a multivariate analysis for OS, comorbidity retained its prognostic impact (HR=2.5, P=0.0003). The proportion of patients dying due to FL was higher among those ≤60 years (74%) and those with a CCI 0–1 (67%). Furthermore, 10-year excess mortality (survival reduction) was more prominent for patients >70 years (30%) and those with a CCI ≥2 (32%). Patients with a CCI ≥2 also had a higher incidence of SM. These data encourage a comprehensive pre-treatment evaluation and a tailored therapeutic approach for all FL patients.